Among the clinical and scientific highlights of this year’s American Heart Association Scientific Sessions 2023 (November 11-13) were latest study data on novel agents targeting apoC3 and ANGPTL3, including effects on TG, TG-rich lipoproteins and remnants, as well as new insights into the effects of different omega-3 fatty acid formulations on membrane lipid dynamics.
Read the reports:
- SHASTA-2: Plozasiran significantly reduces APOC3 and triglycerides
- PROMINENT data show pemafibrate benefits for PAD
- ARCHES-2 data support potential of zodasiran (ARO-ANG3) in mixed dyslipidaemia
- Membrane lipid fluidity may explain discordant EPA vs DHA effects
- MUIR trial results further support TG-lowering with plozasiran
- Solbinsiran shows promise in preclinical research
Reportage by Jenny Bryan